<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02186509</url>
  </required_header>
  <id_info>
    <org_study_id>13P.528</org_study_id>
    <secondary_id>2013-12</secondary_id>
    <nct_id>NCT02186509</nct_id>
  </id_info>
  <brief_title>Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas</brief_title>
  <official_title>Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of alisertib when combined with
      fractionated stereotactic radiosurgery in treating patients with high-grade gliomas that have
      returned after previous treatment with radiation therapy (recurrent). Alisertib may stop the
      growth of tumor cells by blocking an enzyme needed for the cells to divide. Radiation therapy
      uses high energy x rays to kill tumor cells. Stereotactic radiosurgery uses special
      positioning equipment to send a single high dose of radiation directly to the tumor and cause
      less damage to normal tissue. Delivering stereotactic radiosurgery over multiple doses
      (fractionation) may cause more damage to tumor tissue than normal tissue while maintaining
      the advantage of its accuracy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Evaluate the safety and tolerability of the study treatment. II. To determine the maximum
      tolerated dose (MTD) of daily oral alisertib when combined with fractionated stereotactic
      radiation treatment for recurrent high grade glioma.

      SECONDARY OBJECTIVES:

      I. To estimate 6 month progression free survival rate. II. To estimate the median time to
      progression. III. To estimate overall survival. IV. To estimate the impact on quality of life
      (QoL).

      OUTLINE: This is a dose-escalation study of alisertib.

      CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery once daily (QD)
      every weekday for 10 days and receive alisertib orally (PO) twice daily (BID) concurrently
      with radiation therapy for 10 days.

      MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21
      days for up to 18 courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for 1 year and
      then every 4-6 months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2015</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Alisertib</measure>
    <time_frame>Up to 30 days after completion of radiation therapy</time_frame>
    <description>Defined as the dose at which &gt;= 2 patients experience dose-limiting toxicity, graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete or Partial Response</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>95% confidence intervals will be computed. Response was defined by the Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Work Group (RANO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Progression Free Survival at 6 Months</measure>
    <time_frame>At 6 months</time_frame>
    <description>Estimated through the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Survival at 6 Months</measure>
    <time_frame>At 6 months</time_frame>
    <description>Estimated through the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Adult Anaplastic Astrocytoma</condition>
  <condition>Adult Anaplastic Ependymoma</condition>
  <condition>Adult Anaplastic Oligodendroglioma</condition>
  <condition>Adult Brain Stem Glioma</condition>
  <condition>Adult Diffuse Astrocytoma</condition>
  <condition>Adult Giant Cell Glioblastoma</condition>
  <condition>Adult Glioblastoma</condition>
  <condition>Adult Gliosarcoma</condition>
  <condition>Adult Mixed Glioma</condition>
  <condition>Adult Oligodendroglioma</condition>
  <condition>Adult Pilocytic Astrocytoma</condition>
  <condition>Adult Pineal Gland Astrocytoma</condition>
  <condition>Adult Subependymal Giant Cell Astrocytoma</condition>
  <condition>Recurrent Adult Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Alisertib, fractionated stereotactic radiosurgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.
MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hyperfractionated radiation therapy</intervention_name>
    <description>Undergo hyperfractionated radiation therapy</description>
    <arm_group_label>Alisertib, fractionated stereotactic radiosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiosurgery</intervention_name>
    <description>Undergo stereotactic radiosurgery</description>
    <arm_group_label>Alisertib, fractionated stereotactic radiosurgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alisertib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Alisertib, fractionated stereotactic radiosurgery</arm_group_label>
    <other_name>MLN8237</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Alisertib, fractionated stereotactic radiosurgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have a previously histologically or cytologically confirmed high grade
             glioma (astrocytic or oligodendroglial supratentorial tumors grade 3 or 4) that has
             been previously treated with fractionated radiation therapy and now shows evidence of
             recurrence.

          2. Patients must have recovered from the toxic effects of prior therapy.

          3. Patients must have recovered from the effects of surgery. There must be a minimum of
             21 days from the day of surgery to the day of protocol treatment. For core or needle
             biopsy, a minimum of 7 days must have elapsed prior to the day of protocol treatment.

          4. Prior treatment with cytotoxic and biological agents is permissible. There should be
             at least a 2-week break between prior treatment and the protocol treatment.

          5. Prior treatment with fractionated radiation therapy (up to 60Gy) is an eligibility
             criterion, however there should not have been a second course of fractionated
             radiotherapy to the supratentorial area.

          6. One prior single fraction radiosurgical procedure within the treatment field is
             acceptable if V12&lt;5 cc (V12 is the volume of normal brain (outside GTV) receiving 12
             or more Gy). Additional radiosurgical procedures outside of the treatment area are
             acceptable.

          7. Subject must be able to take oral medication and to maintain a fast, is required for 2
             hours before and 1 hour after MLN8237 administration.

          8. ANC &gt; 1500/mm³, platelets &gt; 100,000/mm³, Hgb &gt; 9 g/dL. Values must be obtained without
             need for myeloid growth factor or platelet transfusion support within 14 days of
             registration. However, erythrocyte growth factor is allowed as per published ASCO
             guidelines.

          9. Total bilirubin ≤ ULN, SGOT (AST) and SGPT (ALT)&lt; 1.5 x ULN, within 14 days of
             registration.

         10. Adequate renal function as defined by: calculated creatinine clearance must be ≥40
             mL/minute (Cockcroft-Gault), within 14 days of registration.

         11. Age &gt;18 years.

         12. ECOG performance status &lt;2 (see Appendix I).

         13. Life expectancy of greater than 2 months.

         14. Women of childbearing potential must have a negative β-HCG pregnancy test documented
             within 7 days prior to registration.

         15. Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             4 months after last dose.

         16. Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          1. Known history of uncontrolled sleep apnea syndrome and other conditions that could
             result in excessive daytime sleepiness such as severe chronic obstructive pulmonary
             disease requiring supplemental oxygen.

          2. Systemic infection requiring IV antibiotic therapy within 14 days preceding the first
             dose of study drug, or other severe infection.

          3. Myocardial infarction within 6 months prior to enrollment, New York Heart Association
             (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled
             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active
             conduction system abnormalities. Prior to study entry, any ECG abnormality at
             Screening has to be documented by the investigator as not medically relevant.

          4. Female subject is pregnant or breast-feeding. Confirmation that the subject is not
             pregnant must be established by a negative serum β-human chorionic gonadotropin
             (β-hCG) pregnancy test result obtained during screening. Pregnancy testing is not
             required for post-menopausal or surgically sterilized women.

          5. Patient has received other investigational drugs within 14 days before enrollment

          6. Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          7. Other severe acute or chronic medical or psychiatric condition, including uncontrolled
             diabetes, malabsorption, resection of the pancreas or upper small bowel, requirement
             for pancreatic enzymes, any condition that would modify small bowel absorption of oral
             medications, or laboratory abnormality that may increase the risk associated with
             study participation or investigational product administration or may interfere with
             the interpretation of study results and, in the judgment of the investigator, would
             make the patient inappropriate for enrollment in this study.

          8. Treatment with clinically significant enzyme inducers, such as the enzyme-inducing
             antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin,
             rifapentine or St. John's wort within 14 days prior to the first dose of MLN8237 and
             during the study.

          9. Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or
             hepatitis C. Testing is not required in the absence of clinical findings or suspicion.

         10. Patients have a history of any other malignancy from which the patient has been
             disease-free for less than 2 years, with the exception of adequately treated basal or
             squamous cell carcinoma of skin, superficial bladder cancer or carcinoma in situ of
             cervix, AJCC (version 7.0) stage 0 or I breast cancer, AJCC (version 7.0) stage I, or
             II prostate cancer.

         11. Radiation therapy to more than 25% of the bone marrow. Whole pelvic radiation is
             considered to be over 25%.

         12. Patients who cannot swallow whole tablets (i.e. medication tablets)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenyin Shi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2014</study_first_posted>
  <results_first_submitted>May 16, 2019</results_first_submitted>
  <results_first_submitted_qc>August 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2019</results_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT02186509/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Alisertib, Fractionated Stereotactic Radiosurgery</title>
          <description>CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.
MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Hyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy
Stereotactic radiosurgery: Undergo stereotactic radiosurgery
Alisertib: Given PO
Quality-of-life assessment: Ancillary studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Alisertib, Fractionated Stereotactic Radiosurgery</title>
          <description>CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.
MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Hyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy
Stereotactic radiosurgery: Undergo stereotactic radiosurgery
Alisertib: Given PO
Quality-of-life assessment: Ancillary studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Alisertib</title>
        <description>Defined as the dose at which &gt;= 2 patients experience dose-limiting toxicity, graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</description>
        <time_frame>Up to 30 days after completion of radiation therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alisertib, Fractionated Stereotactic Radiosurgery</title>
            <description>CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.
MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Hyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy
Stereotactic radiosurgery: Undergo stereotactic radiosurgery
Alisertib: Given PO
Quality-of-life assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Alisertib</title>
          <description>Defined as the dose at which &gt;= 2 patients experience dose-limiting toxicity, graded in severity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</description>
          <units>mg dose of Alisertib</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete or Partial Response</title>
        <description>95% confidence intervals will be computed. Response was defined by the Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Work Group (RANO)</description>
        <time_frame>Up to 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alisertib, Fractionated Stereotactic Radiosurgery</title>
            <description>CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.
MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Hyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy
Stereotactic radiosurgery: Undergo stereotactic radiosurgery
Alisertib: Given PO
Quality-of-life assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete or Partial Response</title>
          <description>95% confidence intervals will be computed. Response was defined by the Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Work Group (RANO)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Progression Free Survival at 6 Months</title>
        <description>Estimated through the Kaplan-Meier method.</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alisertib, Fractionated Stereotactic Radiosurgery</title>
            <description>CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.
MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Hyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy
Stereotactic radiosurgery: Undergo stereotactic radiosurgery
Alisertib: Given PO
Quality-of-life assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Progression Free Survival at 6 Months</title>
          <description>Estimated through the Kaplan-Meier method.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Survival at 6 Months</title>
        <description>Estimated through the Kaplan-Meier method.</description>
        <time_frame>At 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Alisertib, Fractionated Stereotactic Radiosurgery</title>
            <description>CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.
MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Hyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy
Stereotactic radiosurgery: Undergo stereotactic radiosurgery
Alisertib: Given PO
Quality-of-life assessment: Ancillary studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Survival at 6 Months</title>
          <description>Estimated through the Kaplan-Meier method.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months from baseline</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Alisertib, Fractionated Stereotactic Radiosurgery</title>
          <description>CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.
MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
Hyperfractionated radiation therapy: Undergo hyperfractionated radiation therapy
Stereotactic radiosurgery: Undergo stereotactic radiosurgery
Alisertib: Given PO
Quality-of-life assessment: Ancillary studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperlipidemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Edema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hpocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Focal seizure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wenyin Shi</name_or_title>
      <organization>Sidney Kimmel Cancer Center at Thomas Jefferson University</organization>
      <phone>215-955-6702</phone>
      <email>Wenyin.Shi@jefferson.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

